Encompass Health Corporation (EHC) Q3 2024 Earnings Call Transcript Summary
Encompass Health Corporation (EHC) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Encompass Health Corporation (EHC) Q3 2024 Earnings Call Transcript:
以下是encompass health公司(EHC)2024年第三季度業績會議呼叫成績單摘要:
Financial Performance:
財務表現:
Encompass Health reported a revenue increase of 11.9% reaching $1.35 billion, and an adjusted EBITDA increase of 13.4% to $269.3 million in Q3 2024.
Discharges increased by 8.8%, with total revenue per discharge growth of 2.5%.
Encompass Health報告營業收入增長11.9%,達到13.5億美元,並調整後的EBITDA增長13.4%,達到26930萬美元,截止到2024年第三季度。
出院人數增長8.8%,每位出院患者的總收入增長2.5%。
Business Progress:
業務進展:
Encompass Health has expanded its capacity by adding 99 beds in Q3, including two new de novo hospitals with a total of 89 beds and an expansion of 10 beds in existing facilities.
They anticipate opening one more de novo, a 61-bed hospital in Houston in 2024, and adding approximately 22 more beds to existing hospitals, marking a move towards full prefabrication in construction to reduce costs and expedite completion.
Encompass Health在第三季度通過增加99張牀位擴大了其能力,其中包括兩家新的全新醫院,共計89張牀位,以及現有設施的10張牀位擴建。
他們預計在2024年在休斯敦開設一家61張牀位的全新醫院,並在現有醫院新增約22張牀位,標誌着向完全預製化施工以降低成本並加快完工速度邁出了一步。
Opportunities:
機會:
The aging US population and the chronic health conditions that accompany aging fuel demand for inpatient rehabilitation services, suggesting a growing market for Encompass Health's services.
隨着美國人口老齡化及老年健康問題的增多,需要接受住院康復服務的需求增加,預示着encompass health服務的市場需求日益增長。
Risks:
風險:
Hurricanes Helene and Milton impacted several operational aspects, including hospital evacuations and damage to facilities, although the financial implications appear to be minor with an estimated expense of less than $1 million for Q4.
颶風赫蓮和米爾頓影響了多個運營方面,包括醫院疏散和設施損壞,儘管在財務影響上似乎較小,預估四季度的開支不到100萬美元。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由人工智能生成。內容準確性無法完全保證。如需更全面詳情,請參閱IR網站。本文僅供投資者參考,不具有任何指導或推薦建議。